Skip to content


Viltepso (viltolarsen) is an oligonucleotide pharmaceutical. Viltolarsen was first approved as Viltepso on 2020-08-12. It is used to treat duchenne muscular dystrophy in the USA. Viltepso's patent is valid until 2031-08-31 (FDA).
Trade Name Viltepso
Common Name Viltolarsen
Indication duchenne muscular dystrophy
Drug Class Antisense oligonucleotides
Get full access now